Javascript must be enabled to continue!
Serum symmetric dimethylarginine concentrations in enalapril- or telmisartan-treated dogs with proteinuric chronic kidney disease
View through CrossRef
IntroductionRenin-angiotensin-aldosterone system inhibition (RAASi) reduces intraglomerular pressure and is a standard therapy for dogs with proteinuric chronic kidney disease (CKD). RAASi can acutely decrease glomerular filtration rate (GFR); however, its effects on the marker of GFR serum symmetric dimethylarginine (SDMA) concentration in dogs have not been specifically evaluated. The objective of this study was to evaluate changes, relative to pretreatment values, in serum SDMA concentrations in dogs with proteinuric CKD receiving RAASi therapy.MethodsThis retrospective study used banked samples from 29 dogs with proteinuric CKD treated with enalapril (0.5 mg/kg PO q12h; n = 16) or telmisartan (1 mg/kg PO q24h; n = 13) alone (n = 22) or in combination with amlodipine if severely hypertensive (n = 7). Serum SDMA, creatinine, and urea nitrogen (SUN) concentrations were measured before and 7 and 30 days after starting RAASi. Percentage and absolute changes in these biomarkers were calculated for each dog and time point. A linear mixed model was used to test whether changes significantly differed from zero (α < 0.05).ResultsOverall, mean ± SEM Day 7 and 30 percentage change in SDMA were − 4.8 ± 3.6% and − 3.2 ± 3.4%, respectively; in creatinine were 7.4 ± 3.3% and 3.0 ± 3.1%, respectively; and in SUN were 22.1 ± 6.8% and 16.7 ± 6.2%, respectively. Mean changes varied according to whether all dogs, those on RAASi alone, or those co-treated with amlodipine were evaluated. In dogs receiving RAASi alone, at day 7, there were significant mean percentual increases in creatinine (9%; p = 0.023) and SUN (23%; p = 0.005), but SDMA was unchanged. In dogs co-treated with amlodipine, a significant absolute decrease in mean SDMA (−2.29 μg/dL; p = 0.026) occurred at days 7 and 30, while mean creatinine was unchanged and mean SUN increased.DiscussionProteinuric dogs receiving RAASi had low-magnitude changes in serum SDMA and creatinine, and moderate-magnitude changes in SUN concentrations. The direction of change in SDMA did not consistently match that of creatinine and SUN.
Title: Serum symmetric dimethylarginine concentrations in enalapril- or telmisartan-treated dogs with proteinuric chronic kidney disease
Description:
IntroductionRenin-angiotensin-aldosterone system inhibition (RAASi) reduces intraglomerular pressure and is a standard therapy for dogs with proteinuric chronic kidney disease (CKD).
RAASi can acutely decrease glomerular filtration rate (GFR); however, its effects on the marker of GFR serum symmetric dimethylarginine (SDMA) concentration in dogs have not been specifically evaluated.
The objective of this study was to evaluate changes, relative to pretreatment values, in serum SDMA concentrations in dogs with proteinuric CKD receiving RAASi therapy.
MethodsThis retrospective study used banked samples from 29 dogs with proteinuric CKD treated with enalapril (0.
5 mg/kg PO q12h; n = 16) or telmisartan (1 mg/kg PO q24h; n = 13) alone (n = 22) or in combination with amlodipine if severely hypertensive (n = 7).
Serum SDMA, creatinine, and urea nitrogen (SUN) concentrations were measured before and 7 and 30 days after starting RAASi.
Percentage and absolute changes in these biomarkers were calculated for each dog and time point.
A linear mixed model was used to test whether changes significantly differed from zero (α < 0.
05).
ResultsOverall, mean ± SEM Day 7 and 30 percentage change in SDMA were − 4.
8 ± 3.
6% and − 3.
2 ± 3.
4%, respectively; in creatinine were 7.
4 ± 3.
3% and 3.
0 ± 3.
1%, respectively; and in SUN were 22.
1 ± 6.
8% and 16.
7 ± 6.
2%, respectively.
Mean changes varied according to whether all dogs, those on RAASi alone, or those co-treated with amlodipine were evaluated.
In dogs receiving RAASi alone, at day 7, there were significant mean percentual increases in creatinine (9%; p = 0.
023) and SUN (23%; p = 0.
005), but SDMA was unchanged.
In dogs co-treated with amlodipine, a significant absolute decrease in mean SDMA (−2.
29 μg/dL; p = 0.
026) occurred at days 7 and 30, while mean creatinine was unchanged and mean SUN increased.
DiscussionProteinuric dogs receiving RAASi had low-magnitude changes in serum SDMA and creatinine, and moderate-magnitude changes in SUN concentrations.
The direction of change in SDMA did not consistently match that of creatinine and SUN.
Related Results
Effects Of angiotensin II and Telmisartan on transient outward potassium and L-type calcium currents in Sprague–Dawley rat atrial myocytes
Effects Of angiotensin II and Telmisartan on transient outward potassium and L-type calcium currents in Sprague–Dawley rat atrial myocytes
Objective
To explore possible electrophysiological mechanisms of single atrial myocyte by evaluating the effects of angiotensinII (AngII) and telmisartan on trans...
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Abstract
Introduction
Immunoglobulin G4-related disease (IgG4-RD) is a recently identified immune-mediated condition that is debilitating and often overlooked. While IgG4-RD has be...
Hemodynamic and clinical effects of enalapril in management of children with congestive heart failure : a randomized, placebo-controlled study
Hemodynamic and clinical effects of enalapril in management of children with congestive heart failure : a randomized, placebo-controlled study
Objective: To assess hemodynamic and clinical effects of Enalapril in treating children with congestive heart failure and possible side effects of Enalapril in pediatric population...
MicroRNA profiles following telmisartan treatment in pancreatic ductal adenocarcinoma cells
MicroRNA profiles following telmisartan treatment in pancreatic ductal adenocarcinoma cells
Background:
Pancreatic ductal adenocarcinoma (PDAC) is the most devastating of all cancers with an extremely poor prognosis. It has few effective and reliable therapeut...
MicroRNA-204 may predict the renal function in patients with chronic kidney disease
MicroRNA-204 may predict the renal function in patients with chronic kidney disease
Background:
Chronic kidney disease significantly affects human health by loss of excretory kidney function. MicroRNAs have potential predictive and therapeutic signific...
#57 Tubular biomarkers in proteinuric kidney diseases
#57 Tubular biomarkers in proteinuric kidney diseases
Abstract
Background and Aims
Proteinuria is not only a biomarker of chronic kidney disease (CKD) and a risk predictor of adverse...
Comparative Study of Olmesartan versus Telmisartan, in Patient with Stage I Hypertension
Comparative Study of Olmesartan versus Telmisartan, in Patient with Stage I Hypertension
Background: Hypertension is one of the most common diseases in the world. It is defined as sustained increase in blood pressure ≥ 140/90 mmHg. The risk of both microvascular & ...
e0188 Enalapril, Irbesartan and Ang-(1-7) prevent atrial tachycardia-induced sodium channel remodelling
e0188 Enalapril, Irbesartan and Ang-(1-7) prevent atrial tachycardia-induced sodium channel remodelling
Purpose
Recent studies indicated that the activation of renin-angiotensin system (RAS) played an important role in the development and recurrence of atrial fibril...

